Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Two Ways To Play: This Is Your Heart On Vytorin


Strengthen your portfolio in good times and bad.

Shares of Merck (MRK) and Schering-Plough (SGP) were under pressure today. Bloomberg reports the companies' joint venture drug Vytorin failed to prevent complications from heart disease.

Vytorin prescription have plunged about a third since January this year when a study called Enhance showed that the drug worked no better than just Zocor alone in reducing buildup in the brain's main artery.

The most recent trial; however, confirms previous studies that the drug reduces the risk of coronary artery disease events, but not the rate of progression of aortic valve disease, according to the study's chief investigator.

SGP dropped as much as -15% today while MRK fell -6.24%.

From the Bull Pen: SGP bulls can be comforted by biotech specialist Professor David Miller's comments, that the good news is the study confirmed the drug's primary use in reducing cardiac events related to fat in the arteries.

From the Bear Cave: Regardless of the Vytorin story, is the picture bright for MRK? Breaking the $35 support level would give bears more ammunition.
< Previous
  • 1
Next >
No positions in stocks mentioned.

The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.

Featured Videos